Anti-CD79 antibody induces B cell anergy that protects against autoimmunity

Journal of Immunology

Volumn 192, Issue 4, 2014, Pages 1641-1650

  Hardy, Ian R ^a   Anceriz, Nadia ^b   Rousseau, François ^b   Seefeldt, Matt B ^a   Hatterer, Eric ^b   Irla, Magali ^c   Buatois, Vanessa ^b   Chatel, Laurence E ^c   Getahun, Andrew ^a   Fletcher, Ashley ^a   Cons, Laura ^b   Pontini, Guillemette ^b   Hertzberg, Nicole A ^a   Magistrelli, Giovanni ^b   Malinge, Pauline ^b   Smith, Mia J ^a   Reith, Walter ^c   Kosco Vilbois, Marie H ^b   Ferlin, Walter G ^b   Cambier, John C ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NOVIMMUNE SA   (Switzerland)

^c UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD79 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; CHEMOPROPHYLAXIS; CLONAL ANERGY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD79; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CLONAL ANERGY; FEMALE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT;

EID: 84896719232     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302672     Document Type: Article

References (45)

1. Edwards, J. C., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D. R. Close, R. M. Stevens, and T. Shaw. 2004. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581.
2. Maloney, D. G., A. J. Grillo-López, C. A. White, D. Bodkin, R. J. Schilder, J. A. Neidhart, N. Janakiraman, K. A. Foon, T. M. Liles, B. K. Dallaire, et al. 1997. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195.
3. Hauser, S. L., E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al HERMES Trial Group. 2008. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358: 676-688.
4. Pescovitz, M. D., C. J. Greenbaum, H. Krause-Steinrauf, D. J. Becker, S. E. Gitelman, R. Goland, P. A. Gottlieb, J. B. Marks, P. F. McGee, A. M. Moran, et al; Type 1 Diabetes TrialNet Anti-CD20 Study Group. 2009. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361: 2143-2152.
5. Merrill, J. T., C. M. Neuwelt, D. J. Wallace, J. C. Shanahan, K. M. Latinis, J. C. Oates, T. O. Utset, C. Gordon, D. A. Isenberg, H. J. Hsieh, et al. 2010. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62: 222-233.
6. Reff, M. E., K. Carner, K. S. Chambers, P. C. Chinn, J. E. Leonard, R. Raab, R. A. Newman, N. Hanna, and D. R. Anderson. 1994. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
7. Uchida, J., Y. Lee, M. Hasegawa, Y. Liang, A. Bradney, J. A. Oliver, K. Bowen, D. A. Steeber, K. M. Haas, J. C. Poe, and T. F. Tedder. 2004. Mouse CD20 expression and function. Int. Immunol. 16: 119-129.
8. Cambridge, G., M. J. Leandro, J. C. Edwards, M. R. Ehrenstein, M. Salden, M. Bodman-Smith, and A. D. Webster. 2003. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48: 2146-2154.
9. Byrd, J. C., S. Kitada, I. W. Flinn, J. L. Aron, M. Pearson, D. Lucas, and J. C. Reed. 2002. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 99: 1038-1043.
10. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
11. Shan, D., J. A. Ledbetter, and O. W. Press. 1998. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 91: 1644-1652.
12. Ahuja, A., J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351-3361.
13. Rovin, B. H., R. Furie, K. Latinis, R. J. Looney, F. C. Fervenza, J. Sanchez-Guerrero, R. Maciuca, D. Zhang, J. P. Garg, P. Brunetta, and G. Appel; LUNAR Investigator Group. 2012. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64: 1215-1226.
14. Leandro, M. J., J. C. Edwards, G. Cambridge, M. R. Ehrenstein, and D. A. Isenberg. 2002. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46: 2673-2677.
15. Perrotta, S., F. Locatelli, A. LaManna, L. Cennamo, P. De Stefano, and B. Nobili. 2002. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br. J. Haematol. 116: 465-467.
16. Weide, R., J. Heymanns, A. Pandorf, and H. Köppler. 2003. Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus 12: 779-782.
17. Li, Y., F. Chen, M. Putt, Y. K. Koo, M. Madaio, J. C. Cambier, P. L. Cohen, and R. A. Eisenberg. 2008. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J. Immunol. 181: 2961-2972.
18. Browne, C. D., C. J. Del Nagro, M. H. Cato, H. S. Dengler, and R. C. Rickert. 2009. Suppression of phosphatidylinositol 3,4,5-trisphosphate production is a key determinant of B cell anergy. Immunity 31: 749-760.
19. Gauld, S. B., R. J. Benschop, K. T. Merrell, and J. C. Cambier. 2005. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 6: 1160-1167.
20. Goodnow, C. C., J. Crosbie, S. Adelstein, T. B. Lavoie, S. J. Smith-Gill, R. A. Brink, H. Pritchard-Briscoe, J. S. Wotherspoon, R. H. Loblay, K. Raphael, et al. 1988. Altered immunoglobulin expression and functional silencing of selfreactive B lymphocytes in transgenic mice. Nature 334: 676-682.
21. Healy, J. I., R. E. Dolmetsch, L. A. Timmerman, J. G. Cyster, M. L. Thomas, G. R. Crabtree, R. S. Lewis, and C. C. Goodnow. 1997. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 6: 419-428.
22. O'Neill, S. K., A. Getahun, S. B. Gauld, K. T. Merrell, I. Tamir, M. J. Smith, J. M. Dal Porto, Q. Z. Li, and J. C. Cambier. 2011. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy. Immunity 35: 746-756.
23. Nossal, G. J., and B. L. Pike. 1980. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc. Natl. Acad. Sci. USA 77: 1602-1606.
24. Benschop, R. J., K. Aviszus, X. Zhang, T. Manser, J. C. Cambier, and L. J. Wysocki. 2001. Activation and anergy in bone marrow B cells of a novel immunoglobulin transgenic mouse that is both hapten specific and autoreactive. Immunity 14: 33-43.
25. Healy, J. I., R. E. Dolmetsch, R. S. Lewis, and C. C. Goodnow. 1998. Quantitative and qualitative control of antigen receptor signalling in tolerant B lymphocytes. Novartis Found. Symp. 215: 137-144; discussion 144-145, 186-190.
26. Vilen, B. J., S. J. Famiglietti, A. M. Carbone, B. K. Kay, and J. C. Cambier. 1997. B cell antigen receptor desensitization: disruption of receptor coupling to tyrosine kinase activation. J. Immunol. 159: 231-243.
27. Anolik, J. H., D. Campbell, R. E. Felgar, F. Young, I. Sanz, J. Rosenblatt, and R. J. Looney. 2003. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48: 455-459.
28. Lissilaa, R., V. Buatois, G. Magistrelli, A. S. Williams, G. W. Jones, S. Herren, L. Shang, P. Malinge, F. Guilhot, L. Chatel, et al. 2010. Although IL-6 transsignaling is sufficient to drive local immune responses, classical IL-6 signaling is obligate for the induction of T cell-mediated autoimmunity. J. Immunol. 185: 5512-5521.
29. Getahun, A., M. J. Smith, I. Kogut, L. F. van Dyk, and J. C. Cambier. 2012. Retention of anergy and inhibition of antibody responses during acute g herpesvirus 68 infection. J. Immunol. 189: 2965-2974.
30. Muraki, M., and S. Honda. 2010. Efficient production of human Fas receptor extracellular domain-human IgG1 heavy chain Fc domain fusion protein using baculovirus/silkworm expression system. Protein Expr. Purif. 73: 209-216.
31. Good, P. 1994. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. Springer Series in Statistics. Springer Publishing, New York, NY.
32. Westfall, P. H., and S. S. Young. 1993. Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment. Wiley Series in Probability and Statistics. John Wiley and Sons, Hoboken, NJ.
33. Yanaba, K., Y. Hamaguchi, G. M. Venturi, D. A. Steeber, E. W. St Clair, and T. F. Tedder. 2007. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179: 1369-1380.
34. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
35. Yu, S., R. Dunn, M. R. Kehry, and H. Braley-Mullen. 2008. B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J. Immunol. 180: 7706-7713.
36. Baudino, L., Y. Shinohara, F. Nimmerjahn, J. Furukawa, M. Nakata, E. Martínez-Soria, F. Petry, J. V. Ravetch, S. Nishimura, and S. Izui. 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181: 6664-6669.
37. Carver, D. J., M. J. Aman, and K. S. Ravichandran. 2000. SHIP inhibits Akt activation in B cells through regulation of Akt membrane localization. Blood 96: 1449-1456.
38. Beers, S. A., R. R. French, H. T. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. Kim, K. L. Cox, et al. 2010. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115: 5191-5201.
39. Roll, P., A. Palanichamy, C. Kneitz, T. Dorner, and H. P. Tony. 2006. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 54: 2377-2386.
40. Bubien, J. K., L. J. Zhou, P. D. Bell, R. A. Frizzell, and T. F. Tedder. 1993. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J. Cell Biol. 121: 1121-1132.
41. Gong, S., and M. C. Nussenzweig. 1996. Regulation of an early developmental checkpoint in the B cell pathway by Ig beta. Science 272: 411-414.
42. Pelanda, R., U. Braun, E. Hobeika, M. C. Nussenzweig, and M. Reth. 2002. B cell progenitors are arrested in maturation but have intact VDJ recombination in the absence of Ig-alpha and Ig-beta. J. Immunol. 169: 865-872.
43. Bannish, G., E. M. Fuentes-Pananá, J. C. Cambier, W. S. Pear, and J. G. Monroe. 2001. Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J. Exp. Med. 194: 1583-1596.
44. de Haij, S., J. H. Jansen, P. Boross, F. J. Beurskens, J. E. Bakema, D. L. Bos, A. Martens, J. S. Verbeek, P. W. Parren, J. G. van de Winkel, and J. H. Leusen. 2010. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 70: 3209-3217.
45. Waldron-Lynch, F., O. Henegariu, S. Deng, P. Preston-Hurlburt, J. Tooley, R. Flavell, and K. C. Herold. 2012. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci. Transl. Med 4: 118ra12.